ClearPoint Neuro stock tumbles on uniQure trial setback

uniQure (QURE) shares fell 37% after four-year Huntington’s gene therapy study results missed a key test, though three-year data showed significant slowing of disease decline. Analysts maintained bullish ratings, citing strong three-year results and potential FDA approval. The stock closed at $24.51, its worst day since November 2025.

uniQure reported 48-month data for AMT-130, its gene therapy for Huntington's disease. The study showed a 44% slowing of cUHDRS decline and a 61% slowing on TFC, with the latter reaching statistical significance. The company noted differences in external-control datasets and conducted sensitivity analyses. AMT-130 was generally well-tolerated, with no new serious adverse events. uniQure's BLA submission is based on 36-month data, and the company awaits FDA review.

uniQure N.V. [QURE] reported that its AMT-130 treatment showed sustained slowing of Huntington's disease progression at 36 and 48 months, with improvements in functional capacity and a favorable safety profile. The company highlighted the stability in Total Functional Capacity (TFC) as clinically meaningful and announced that regulatory submissions are advancing.

UniQure N.V. (QURE) shares dropped 37% after reporting Phase I/II trial data for Huntington's disease treatment. The 48-month study showed 44% slowing of disease progression, but the result was not statistically significant. The stock price fell to $24.40, down from $39.11.

Dow Jones fell 100 points, while Carnival (CCL) reported Q3 earnings of $1.43 per share, beating estimates. NASDAQ and S&P 500 also saw mixed trading. BIO-Key (BKYI) and SoundThinking (SSTI) shares surged on strategic news. NewGenIvf (NIVF) and Triller (ILLR) shares dropped significantly.

UniQure (QURE) reported 36- and 48-month data from its AMT-130 Huntington's disease trials, showing slowed disease progression. The FDA may use 3-year data for BLA submission. QURE stock is down 45.15% to $21.45.